Literature DB >> 10634264

Donepezil for Huntington's disease.

H H Fernandez1, J H Friedman, J Grace, S Beason-Hazen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10634264     DOI： 10.1002/1531-8257(200001)15:1<173::aid-mds1032>3.0.co;2-t

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  10 in total

1.  Treatment of huntington disease.

Authors:  Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

2.  Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review.

Authors:  Joe John Vattakatuchery; Renjith Kurien
Journal:  World J Psychiatry       Date:  2013-09-22

Review 3.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 4.  Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?

Authors:  Christopher Christodoulou; William S MacAllister; Nancy A McLinskey; Lauren B Krupp
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 5.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

6.  Treatment of Irritability in Huntington's Disease.

Authors:  Erik van Duijn
Journal:  Curr Treat Options Neurol       Date:  2010-07-10       Impact factor: 3.598

Review 7.  Cell Therapy Strategies vs. Paracrine Effect in Huntington's Disease.

Authors:  Wooseok Im; Manho Kim
Journal:  J Mov Disord       Date:  2014-04-30

Review 8.  Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.

Authors:  Gary X D'Souza; Henry J Waldvogel
Journal:  J Huntingtons Dis       Date:  2016-12-15

Review 9.  Neuromuscular Junction Impairment in Amyotrophic Lateral Sclerosis: Reassessing the Role of Acetylcholinesterase.

Authors:  Maria-Letizia Campanari; María-Salud García-Ayllón; Sorana Ciura; Javier Sáez-Valero; Edor Kabashi
Journal:  Front Mol Neurosci       Date:  2016-12-27       Impact factor: 5.639

10.  Varenicline improves motor and cognitive symptoms in early Huntington's disease.

Authors:  Ailsa L McGregor; Jo Dysart; Malcolm D Tingle; Bruce R Russell; Rob R Kydd; Gregory Finucane
Journal:  Neuropsychiatr Dis Treat       Date:  2016-09-19       Impact factor: 2.570
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.